Horizon Pharma plc Announces the U.S. Patent and Trademark

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets

DUBLIN, IRELAND--(Marketwired - Mar 14, 2016) - Horizon Pharma plc ( NASDAQ : HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/954,082, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire May 31, 2022. After issuance, Horizon and Aralez Pharmaceuticals Inc. ( NASDAQ : ARLZ ) ( TSX : ARZ ) plan to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

About VIMOVO VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for use in children younger than 18 years of age. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond six months. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider. For Full Prescribing Information please see  www.VIMOVO.com .

Important Safety Information

  • Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen, a component of VIMOVO, may increase the chance of a heart attack or stroke, which can be fatal. This chance increases with longer use and in people who have heart disease or risk factors for heart disease.
  • VIMOVO should not be used before or after a type of heart surgery called coronary artery bypass graft (CABG).
  • NSAID-containing medications like VIMOVO may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer. These problems can happen without warning and can lead to death. Older patients may have a greater chance of developing these problems.

VIMOVO is not right for everyone, including patients who have had an asthma attack, hives or other allergic reaction with aspirin or any other NSAID medicine, patients who are allergic to any of the ingredients in VIMOVO or women in late stages of pregnancy.

Serious allergic reactions, including skin reactions, can occur without warning and can be life-threatening; discontinue use of VIMOVO at the first appearance of a skin rash or if you develop sudden wheezing; swelling of the lips, tongue or throat; fainting or problems swallowing.

VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider.

Tell your health care provider right away if you develop signs of active bleeding from any source.

VIMOVO can lead to onset of new hypertension or worsening of existing high blood pressure, either of which may contribute to an increased risk of a heart attack or stroke.

Speak with your health care provider before starting VIMOVO if you

  • Have a history of ulcers or bleeding in the stomach or intestines
  • Have heart problems, high blood pressure, or are taking high blood pressure medications
  • Have kidney or liver problems

Tell your doctor about all of the medicines you take, prescription and non-prescription drugs, including clopidogrel, vitamins and herbal supplements. VIMOVO may affect how other medicines work and other medicines may affect how VIMOVO works.

VIMOVO may increase your risk of getting severe diarrhea. Call your doctor right away if you have watery stool, stomach pain and fever that does not go away.

Talk to your health care provider about your risk for bone fractures and developing low levels of magnesium if you take VIMOVO for a long period of time.

Talk to your health care provider about your risk for developing low levels of magnesium if you take VIMOVO for a long period of time.

The most common side effects of VIMOVO include: inflammation of the lining of the stomach, indigestion, diarrhea, stomach ulcers, abdominal pain and nausea.

For more information on VIMOVO, please see the  Medication Guide  and  Full Prescribing Information.

About Horizon Pharma plc   Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com . Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the issuance of a patent based on the Notice of Allowance from the U.S. Patent and Trademark Office, the expected term of the patent, if issued, potential patent protection for VIMOVO and plans to list any newly issued patent in the FDA's Orange Book. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether the administrative processes required for the issuance of a patent as indicated in the Notice of Allowance will be completed in a timely matter or at all, whether the patent, if issued as indicated in the Notice of Allowance, will provide sufficient protection and market exclusivity for VIMOVO, whether any patents covering VIMOVO may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations Investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications gcurtis@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 97

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 43

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 75

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 0

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 177

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 39

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 34

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading

Top 5 Most Recently Viewed Articles

Tecsys Applauds 2026 Supply Chain Trailblazers

Updated Category News Views 26

Celebrating Supply Chain Game-Changers Diving headfirst into the world of supply chains at Tecsys's signature event, the User Conference in Nashville, showcased this year's champions who took the bull by the horns. These aren’t mere button pushers. They’re the powerhouses of healthcare and distribution, pushing operational performance to new heights. Driving Supply...

Continue Reading
Key Insights on Icelandic Salmon's Upcoming Q2 Results Webinar

Updated Category News Views 129

Exciting Presentation of Icelandic Salmon's Q2 Results Icelandic Salmon is gearing up to unveil its second quarter results for 2025. This exciting upcoming event is slated to take place on a Thursday via a Teams webinar, providing a platform for a detailed overview of the company's performance. Details of the Presentation Hosted by the esteemed CEO Bjørn Hembre alongside...

Continue Reading
TRG Screen Launches Xmon AI Assist for Enhanced Data Insights

Updated Category News Views 225

Revolutionizing Data Management with AI Technology In today's fast-paced financial landscape, organizations are constantly seeking tools that streamline operations and enhance decision-making capabilities. TRG Screen has risen to the occasion with the introduction of Xmon AI Assist, a cutting-edge innovation designed to transform how financial institutions manage their...

Continue Reading
Crypto Analyst Raoul Pal Discusses the Current Banana Zone Trends

Updated Category News Views 379

Raoul Pal’s Insights on the Current Crypto Market U.Today - Raoul Pal, the founder and CEO of Real Vision, is widely recognized for his expertise in cryptocurrency and investing. Recently, he took to the social media platform X (formerly known as Twitter) to engage with his followers about the prevailing conditions in the crypto market and the future outlook for...

Continue Reading
Investing $1000 in Gold Fields: A 5-Year Growth Journey

Updated Category News Views 230

The Incredible Return on Gold Fields Investment Gold Fields (NYSE: GFI) has remarkably outperformed the market in the past five years, showcasing an annualized return of 27.98%—a substantial difference over standard investment returns. With a current market capitalization of $38.14 billion, Gold Fields stands out as a worthwhile investment opportunity. What If You...

Continue Reading